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Background: The factors involved in the progression from Plasmodium falciparum infection to severe malaria (SM)
are still incompletely understood. Altered antibody and cellular immunity against P. falciparum might contribute to
increase the risk of developing SM.
Methods: To identify immune responses associated with SM, a sex- and age-matched case–control study was
carried out in 134 Mozambican children with SM (cerebral malaria, severe anaemia, acidosis and/or respiratory
distress, prostration, hypoglycaemia, multiple seizures) or uncomplicated malaria (UM). IgG and IgM against P.
falciparum lysate, merozoite antigens (MSP-119, AMA-1 and EBA-175), a Duffy binding like (DBL)-α rosetting domain
and antigens on the surface of infected erythrocytes were measured by ELISA or flow cytometry. Plasma
concentrations of IL-12p70, IL-2, IFN-γ, IL-4, IL-5, IL-10, IL-8, IL-6, IL-1β, TNF, TNF-β and TGF-β1 were measured using
fluorescent bead immunoassays. Data was analysed using McNemar’s and Signtest.
Results: Compared to UM, matched children with SM had reduced levels of IgG against DBLα (P< 0.001), IgM
against MSP-119 (P= 0.050) and AMA-1 (P= 0.047), TGF-β1 (P <0.001) and IL-12 (P= 0.039). In addition, levels of IgG
against P. falciparum lysate and IL-6 concentrations were increased (P= 0.004 and P= 0.047, respectively). Anti-DBLα
IgG was the only antibody response associated to reduced parasite densities in a multivariate regression model
(P= 0.026).
Conclusions: The lower levels of antibodies found in children with SM compared to children with UM were not
attributable to lower exposure to P. falciparum in the SM group. IgM against P. falciparum and specific IgG against a
rosetting PfEMP1 domain may play a role in the control of SM, whereas an imbalanced pro-inflammatory cytokine
response may exacerbate the severity of infection. A high overlap in symptoms together with a limited sample size
of different SM clinical groups reduced the power to identify immunological correlates for particular forms of SM.
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In countries endemic for Plasmodium falciparum, severe
malaria (SM) was responsible for approximately 0.7 mil-
lion deaths in 2010, predominantly children under five
years of age [1]. Reduction of case fatality rates and mor-
bidity is hampered by an incomplete understanding of
the parasite and host factors involved in the pathophysi-
ology of life-threatening disease. Progression from infec-
tion to severe clinical malaria is probably multi-factorial,
including sequestration of infected erythrocytes (IEs) in
vital organs and mechanical obstruction of blood flow,
limited malaria-specific antibody immunity and deregu-
lated inflammatory responses to P. falciparum [2].
Antibodies targeting blood stage parasite antigens are
acquired after exposure to P. falciparum [3] and may
contribute to protection from SM by reducing parasite
density [4]. Specifically, antibodies against P. falciparum
erythrocyte membrane protein 1 (PfEMP1) have been
suggested to block formation of rosettes [5] and cytoad-
hesion of IEs to specific host receptors [6]. Several studies
have reported associations between antibody responses
and risk of SM in young children [7-12]. However, con-
clusions are contradictory, some showing low immuno-
globulin G (IgG) levels in children with severe anaemia
(SA) [7,10] compared to uncomplicated malaria (UM),
others reporting no associations [9] or even opposite
trends for cerebral malaria (CM) [7]. In addition, the role
of immunoglobulin M (IgM) antibodies in children with
SM has been much less explored [9,12], although reduced
IgM responses have been observed in adults with CM
[13,14].
In addition to antibodies, cytokines such as interleu-
kin (IL)-12, interferon (IFN)-γ and tumor necrosis fac-
tor (TNF) have been shown to be involved in the
control of P. falciparum infection [15-17]. However, the
excessive production of pro-inflammatory cytokines,
such as TNF and IL-6, may damage host tissues, in-
crease the expression of adhesion molecules on endo-
thelial cells and enhance parasite cytoadhesion [18]. The
regulation of pro-inflammatory cytokines production by
IL-10 or transforming growth factor (TGF)-β1 seems to
be a key factor in preventing acute pathology [19-21]
and, overall, the fine balance between pro-inflammatory
versus immuno-regulatory cytokines is suggested to de-
termine the outcome of P. falciparum infection [22].
Combined information on both antibody and cytokine
responses is needed to understand the role of immunity
in the progression of malaria infection to SM, and to de-
velop rational strategies that reduce mortality and mor-
bidity associated to SM. Remarkably, there is scarce data
on antibody responses in children with signs of severity
other than SA and CM such as prostration, acidosis
and/or respiratory distress (ARD) or multiple seizures
(MS), which are among the most prevalent forms of SMin some endemic areas [23]. In the present study, the as-
sociation of SM with low antibody responses and an exa-
cerbated pro-inflammatory cytokine response was tested
in Mozambican children. IgG and IgM against parasite
lysate, merozoite antigens and P. falciparum antigens on
the surface of IEs, as well as plasma cytokines and che-
mokines, were compared between children with different
clinical presentations of SM and children with UM,
matched by sex and age.
Methods
Study area
The area of study was located in the Manhiça District,
southern Mozambique. Detailed descriptions of the area
have been reported elsewhere [24]. Briefly, Manhiça is
characterized by a perennial malaria transmission with
some seasonality and of moderate intensity, mostly at-
tributable to P. falciparum. The majority of SM cases
occur in children under five years of age. Prostration,
ARD and SA are the most common clinical presenta-
tions, with coma being infrequent and slightly shifted to
older children [23].
Study design and patients
Between April and November 2006, a sex and age
(+/−3 months) matched case–control study was con-
ducted, with a primary aim of characterizing the cytoad-
hesion phenotypes of P. falciparum isolates [25].
Children under five years of age attending the Manhiça
District Hospital with a clinical diagnosis of P.
falciparum malaria were recruited after written informed
consent was given by their parents or guardians. Clinical
malaria was defined as the presence of fever (axillary
temperature ≥37.5 °C) with an asexual P. falciparum
parasitaemia of ≥500/μL by microscopic examination of
Giemsa-stained blood smears; this definition of malaria
has a sensitivity and specificity of >90% in children from
Manhiça [26]. Cases were children presenting with clin-
ical malaria and at least one of the following definitions
of SM [27]: CM (Blantyre Coma Score ≤2), SA (packed
cell volume <15% or hemoglobin <5 g/dL), ARD (lac-
tate >5 mM and/or chest indrawing or deep breathing),
prostration (inability to sit or breastfeed in children old
enough to do so), hypoglycaemia (blood glucose
<2.2 mM) and MS (≥2 convulsions in the preceding
24 h) . Controls were outpatient children with malaria
not showing any of the mentioned signs of severity and
able to take oral medication (UM group). All patients
were reviewed by the study pediatrician to confirm that
malaria was the sole or principal cause of the disease.
Children with positive bacteraemia were excluded from
the study. Malnutrition was defined as the presence of
marasmus or kwashiorkor by clinical examination or as
a mid-upper arm circumference <12.5 cm in children
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ted with intravenous quinine until able to switch to oral
therapy, while UM controls were treated following
Mozambican national guidelines at that time (artesunate
plus sulphadoxine-pyrimethamine). The study was
approved by the National Mozambican and the Hospital
Clinic of Barcelona Ethics Review Committees.
Sample collection
Before treatment, peripheral blood was taken by
venipuncture into a tube containing lithium heparin,
and 2 drops of blood were spotted onto filter paper
(Schleicher & Schuell; n° 903TM). Biochemical determi-
nations (alanine aminotransferase, bilirubin and creatin-
ine) and full blood counts were performed using Vitros
DT60 and Sysmex Kx21 analyzers, respectively. Lactate
was determined using Lactate ProW (Fact Canada) at the
bed side. After centrifugation, plasma was stored at
−80 °C, erythrocyte pellets were Buffy-coat depleted,
washed 3 times in phosphate-buffered saline (PBS) and
cryopreserved in glycerolyte solution.
Parasite density and multiplicity of infection
DNA was extracted from a 50 ml blood drop onto filter
paper with QIAamp DNA Mini Kit (Qiagen), and resus-
pended in 150 ml of water. Five ml of DNA samples,
tested in triplicate, were used to measure parasite dens-
ity by a real-time quantitative PCR (qPCR) targeting the
P. falciparum 18 S ribosomal RNA gene, as described
elsewhere [28]. Multiplicity of infection (MOI) was
determined by nested PCR-typing of the polymorphic
regions of msp-1 and msp-2 genes [29], and estimated as
the highest number of msp-1 or msp-2 alleles in the
sample.
Enzyme-linked immunosorbent assays (ELISA)
IgG and IgM antibodies were measured against the re-
combinant proteins merozoite surface protein 1 (MSP-
119, 19 kD fragment, 3D7 [30]), erythrocyte binding
antigen 175 (EBA-175, F2 region, CAMP [31]), apical
membrane antigen 1 (AMA-1, full ectodomain, 3D7
[32]) and a Duffy binding like alpha (DBLα) domain
from a PfEMP1 involved in rosetting through adhesion
to complement receptor 1 (R29var1 minimal domain,
[33]), all produced at the International Centre for Gen-
etic Engineering and Biotechnology (New Delhi, India).
High-binding 96-well microplates (Nunc Maxisorp)
were coated with 200 ng/well of recombinant protein in
0.05 M carbonate-bicarbonate buffer. Plates were
washed with 0.05% Tween-20 in PBS (PBS-Tween),
blocked with 2% bovine serum albumin (BSA) in PBS-
Tween for 8 h at 4 °C and washed again. One hundred
μl of plasma at 1/200 dilution along with positive (pool
from 8 hyper-immune Mozambican adults) and negativecontrols (9 unexposed Europeans) were added in dupli-
cate to wells. After incubation overnight at 4 °C,
peroxidase-conjugated goat anti-human IgG or IgM sec-
ondary antibodies (Sigma) were added at 1/30000 and 1/
2000, respectively. After 1 h of incubation and washing,
100 μl/well of a phosphate solution with 0.012% of H2O2
substrate and o-phenylendiamine chromagen were added
for 5 min and the colorimetric reaction was stopped
with 25 μl/well of H2SO4. Specific reactivity of plasmas
was obtained as optical density (OD) values measured at
492 nm (Multiskan EX, Labsystems) and normalized by
dividing OD of each sample by the OD of the positive
control run in each plate.
To measure antibodies to P. falciparum lysate, the
3D7 and HB3 clones (provided by the Malaria Research
and Reference Reagent Resource Center, MR4) from
asynchronous cultures at 5% parasitaemia were homoge-
nized in PBS at 1% haematocrit by a minimum of three
freeze-thawing steps and mixed (1:1). A lysate of unin-
fected erythrocytes was used to determine unspecific
recognition. Coating was done with 50 μl of erythrocyte
extract and plasma was added at 1/1600 dilution. Reac-
tion was performed as described above. OD of unin-
fected lysate wells was subtracted from OD of infected
lysate wells, and values were normalized against the
positive control run in each plate.
Antibodies to IEs surface antigens
Five paediatric isolates (three from SM patients [MOZ1,
MOZ2 and MOZ4] and two from UM patients [MOZ3
and MOZ5]) and two placental isolates from O blood
group individuals [25,34], were tested for antibody rec-
ognition. MOZ2 was adapted to in vitro culture,
whereas the remaining isolates were used in antibody
measurements without in vitro expansion. IgG were
also measured against four laboratory clones with differ-
ent receptor binding phenotypes: R29 (rosetting, [35]),
ITGICAM (ICAM-1, [36]), FCR3CSA (CSA, [37]) and
E8BCD36 (CD36, [38]). The study samples, plus negative
and positive controls, were tested blindly in a single
assay against each parasite. Briefly, cryopreserved ring-
stage parasites were thawed in a sorbitol gradient and
cultured to late trophozoites following standard meth-
ods. Cells were washed three times in PBS and resus-
pended at 1% of haematocrit and 1-5% parasitaemia in
1% BSA-PBS solution. Five μl of plasma were added to
95 μl/well of erythrocyte suspension, incubated for
30 min at room temperature and stained for 30 min with
100 μl of polyclonal rabbit anti-human IgG (DakoCyto-
mation) at 1/200. Subsequently, cells were incubated
with 100 μl of AlexaFluorW-conjugated donkey anti-
rabbit IgG (Invitrogen) diluted at 1/1000 and 10 mg/mL
ethidium bromide for 30 min in darkness. Samples were
washed three times with PBS-BSA between incubations.
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Becton-Dickinson FACSCalibur flow cytometer. Reactiv-
ity against IEs surface antigens was expressed as the dif-
ference between the mean fluorescence intensity (MFI)
of IEs and the MFI of uninfected red blood cells.
Cytokines and chemokines
Concentrations (pg/mL) of IL-12p70, IL-2, IFN-γ, IL-4,
IL-5, IL-10, IL-8, IL-6, IL-1β, TNF, TNF-β and TGF-β1 in
plasma were measured using fluorescent bead immunoas-
says (Human Th1/Th2 11plex and Human TGF-β1 Flow-
Cytomix Simplex kits, Bender MedSystems, Austria)
following manufacturer’s instructions. Beads fluorescence
was acquired with a Becton-Dickinson FACSCanto II and
analysed in FlowCytomix Pro2.2.1 software (Bender Med-
Systems). Concentration of each analyte was obtained by
extrapolating fluorescence intensity to a 7-point dilution
standard curve supplied by the manufacturer. Any value
below the limits of detection was given a value of half the
detection limit for that cytokine.
Statistical methods
Prevalence of recognition of parasites and recombinant
proteins by antibodies in children was considered posi-
tive if MFI or normalized OD values were above the
mean of the negative controls plus three standard devia-
tions for each antigen. Spearman’s rank correlations
were performed to evaluate correlations between im-
munological parameters. Comparisons between matched
case–control pairs for categorical variables were done
using McNemar´s chi-squared, and reported as the
number of pairs with a divergent result between SM and
UM. Continuous variables were analysed using Sign test,
and reported as the median difference between SM and
UM values. Children were stratified by SM clinical pre-
sentations, and compared to their matched controls. Ad-
justment for multiple comparisons was done by Monte
Carlo permutation tests with 1000 random permutations
[39]. Associations between immune responses and para-
site qPCR densities were assessed by multivariate linear
regression with log-transformed parasite density as the
outcome and log-transformed antibodies or cytokines as
independent variables. All data collected were analysed
using Stata version 10.0 (Stata Corporation). P-values
<0.05 were considered statistically significant.
Results
Characteristics of the study participants
Among 142 children recruited, four tested negative for
P. falciparum by qPCR and were excluded together with
their matched pairs. Therefore, 134 children (67 case–
control pairs) were finally analysed. The clinical charac-
teristics of the patients are summarized in Table 1.
Prostration, ARD, SA and MS were the most prevalentsymptoms of severity, whereas hypoglycaemia and CM
were only described in five and three children, respect-
ively. Forty-four (65%) children presented with two or
more SM criteria. The 23 cases with a single criterion
of severity distributed as follows: 13 prostration, 6 MS,
3 SA and 1 ARD. Three SM patients died yielding a
case-fatality rate of 2%, and two were transferred to Ma-
puto Central Hospital. Parasite densities by qPCR were
higher in SM cases than in paired controls, but this dif-
ference was not statistically significant (P= 0.087). Chil-
dren with SM or UM did not differ in malnutrition,
indirect clinical indicators of AIDS (oral candidiasis) or
in the number of days with clinical symptoms prior to
recruitment. Pre-treatment with an anti-malarial was
only reported for one patient with SM. Previous history
of SM was more common among children with SM (11
[16%]) than in children with UM (3 [4%]; divergent
pairs = 13 [18%], P= 0.037).
Antibodies and malaria severity
Prevalence and levels of IgG against DBLα were signifi-
cantly lower in children with SM compared to their
matched controls (P= 0.032 and P< 0.001, respectively),
whereas no differences were found for IgG against mero-
zoite antigens (Figure 1A). In contrast, IgG levels against
P. falciparum lysate were significantly higher in children
with SM than in matched controls (P= 0.004; Figure 1B).
Recognition of antigens on the surface of IEs did not dif-
fer between SM and UM children for any of the para-
sites tested (Table 2). Overall, IgG prevalence was
highest for R29 and E8BCD36 IEs, and lowest for CSA
binding IEs (FCR3CSA) and placental isolates. A similar
seroprevalence was found for IEs isolated from SM
patients (MOZ1, MOZ2, MOZ4) or UM patients
(MOZ3, MOZ5; Table 2). The number of IgM respon-
ders against MSP-119 and AMA-1 was lower in SM
(P= 0.038 and P= 0.024, respectively), and a similar but
not significant trend was found for DBLα (Figure 2A).
Likewise, anti-MSP-119 and AMA-1 IgM levels were
lower in SM compared to their UM pairs (P= 0.050 and
P= 0.047, respectively). In general, different antibody
responses correlated weakly (Additional file1), with the
exception of IgG against EBA-175 and MSP-119 (Spear-
man’s rho= 0.8635, P< 0.001) and IgM against EBA-175
and AMA-1 (Spearman’s rho= 0.8595, P< 0.001).
A stratified analysis by SM clinical presentations
showed that levels of IgG against DBLα were lower both
for SA (P= 0.031), ARD (P= 0.015) and prostration
(P= 0.002) compared to their respective matched con-
trols (see Additional file2). Similar to the main analysis,
no differences were found for other recombinant anti-
gens or for IgG against IEs surface (data not shown).
Levels of IgM were significantly lower in children with
SA, ARD and prostration for at least one of the antigens
Table 1 Characteristics of the study population
Parametera Clinical groups
SM (N=67) UM (N=67) Matched comparisonc P
Demographic data
Age (months) 28 (16, 39) 29 (15, 38) - -
Males, n (%) 42 (63) 42 (63) - -
Physical findings
Temperature (°C) 38.6 (37.9, 39.2) 38 (36.4, 39.5) 0.3 (−0.7, 2.2) 0.227
Weight (kg) 11.1 (8.9, 13) 10.9 (9.6, 12.8) 0 (−1.6, 1.2) 1.000
Malnutrition, n (%) 5 (8) 2 (3) 4 (6) 0.453
Oral candidiasis, n (%) 1 (1) 1 (1) 2 (3) 1.000
Hepatomegaly, n (%) 13 (19) 2 (3) 13 (19) 0.005
Splenomegaly, n (%) 35 (52) 12 (18) 35 (52) <0.001
N° of days with symptomsb 1 (1, 3) 1 (1, 2) 0 (0, 1) 0.192
Laboratory parameters
Parasitaemia by qPCR, (×103/μL) 34.2 (7.5, 151.3) 13.3 (1.7, 51.6) 2.1 (−1.0, 21.8) 0.087
Parasitaemia by microscopy, (×103/μL) 40.4 (17.3, 99.3) 34.7 (11.5, 71.3) 12.9 (−10.3, 58.3) 0.036
Multiplicity of infection 3 (2, 4) 3 (3, 4) 0 (−1, 2) 0.070
Packed cell volume (%) 26 (16, 31) 31 (28, 34) −6 (−15, 0) <0.001
Platelets (×109/L) 117 (70, 185) 145 (92, 192) −38 (−110, 43) 0.043
Glucose (mM) 5.8 (4.6, 7) 5.8 (5.3, 6.9) −0.1 (−1.6, 1.2) 0.702
White blood cells (×109/L) 10 (6.8, 12.7) 9.1 (7.2, 11.5) 0.7 (−2.8, 3.5) 0.110
Lymphocytes (%) 35.5 (24.7, 46) 40.6 (30.2, 50.8) −7.6 (−19.0, 9.1) 0.008
Neutrophils (%) 56.9 (42.9, 67.1) 53.7 (36.9, 65.3) 5.8 (−5.1, 10.2) 0.043
Creatinin (U/L) 34 (30, 38) 34 (30, 39) −1 (−6, 6) 0.470
Bilirubin (μM) 24 (14, 37) 13 (10, 21) 10 (−1, 23) <0.001
ALTc (U/L) 31.5 (19, 39) 28 (1, 36) 4 (−11, 15) 0.376
Lactate (mM) 3.8 (2.3, 5.1) 2.3 (1.9, 3.2) 1.0 (−0.3, 2.4) 0.001
SM symptoms
Prostration, n (%) 50 (75)
ARD c, n (%) 34 (51)
Severe anaemia, n (%) 22 (33)
Multiple seizures, n (%) 19 (28)
Hypoglycaemia, n (%) 5 (8)
Cerebral malaria, n (%) 3 (5)
N° of SM symptoms, n (%):
One 23 (34)
Two 27 (40)
≥ three 17 (25)
a Presented as medians (inter-quartile range), except when indicated. qPCR, quantitative real-time polymerase chain reaction; ALT, alanine aminotransferase; ARD,
acidosis and/or respiratory distress.
b Fever, cough or vomits.
c Matched comparison reports the median difference (inter-quartile range) between SM and UM values for continuous variables or the number (%) of divergent
pairs for categorical variables. P-values calculated using McNemar´s or Sign test for matched pairs. All comparisons were corrected by the Monte Carlo
permutation test (1000 random permutations).
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hypoglycaemia could not be assessed separately due to
the low prevalence of these groups (Table 1).A linear regression model including all antibody
responses showed that IgG against DBLα was the only







































































Figure 1 IgG antibody responses to merozoite antigens (A) and P. falciparum (Pf) lysate (B). Seroprevalence is represented by bars as the %
of responders; plasma levels are represented by dot plots, with horizontal lines indicating median values. Data from children with SM is shown as
shaded bars/dots; data from children with UM is shown as open bars/dots. Results of matched comparisons are reported in the x axis as the
number (%) of divergent pairs for IgG seroprevalence, and the median difference (inter-quartile range) of IgG levels between SM and UM. P-values
were calculated using McNemar’s or Sign test. All comparisons were corrected by the Monte Carlo permutation test (1000 random permutations).
Thresholds for seroprevalence (OD): MSP-119 = 0.560, EBA-175= 0.628, AMA-1= 0.578, DBLα= 0.489, P. falciparum lysate = 0.034. Median difference
(inter-quartile range) of IgM levels against uninfected erythrocytes lysate between SM and UM=−0.01 [−0.03, 0.01], P= 0.175.
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parasite densities per a two-fold increment in IgG levels
was 0.27 when both SM and UM children were included
in the analysis ([95% confidence interval [CI] 0.08, 0.85],
P= 0.026) and 0.11 including only SM cases ([95% confi-
dence interval [CI] 0.02, 0.72], P= 0.022), but the effectTable 2 IgG antibody responses to infected erythrocytes surf
Parasitesa Seroprevalenceb (N = 67 pairs) Ig
SM UM Matched comparison P S
R29 64 (96) 65 (97) 5 (7) 1.000 1
FCR3CSA 8 (12) 11 (16) 15 (22) 0.608 7
E8BCD36 58 (87) 62 (93) 14 (21) 0.414 6
ITGICAM1 11 (16) 15 (22) 24 (36) 0.300 1
MOZ1 17 (25) 18 (27) 25 (37) 0.666 2
MOZ2 40 (60) 36 (54) 34 (51) 0.367 1
MOZ3 32 (48) 30 (45) 34 (51) 0.611 2
MOZ4 47 (70) 44 (66) 27 (40) 0.704 5
MOZ5 51 (76) 56 (83) 24 (36) 0.293 8
PLC1 0 (0) 3 (4) 3 (4) 0.255 5
PLC2 0 (0) 3 (4) 3 (4) 0.255 1
a MOZ, isolates from Mozambican children; PLC, placental isolates from Mozambica
b Presented as the number (%) of responders. Matched comparison reports the num
Thresholds for seroprevalence (MFI): R29 = 5.1, FCR3CSA = 10.1, E8BCD36 = 2.6, ITGICAM
PLC1 = 107.6, PLC2 = 42.9.
c Presented as medians (inter-quartile range) of MFI values. Matched comparison re
and UM. P-values calculated using Sign test.
All comparisons were corrected by the Monte Carlo permutation test (1000 randomwas not observed among UM controls (1.34 [95% CI
0.28, 6.50], P= 0.712).
Cytokines and chemokines and malaria severity
Children with SM had significantly higher IL-6 concen-
trations in plasma than children with UM (P= 0.047,ace antigens
G levelsc (N = 67 pairs)
M UM Matched comparison P
1.5 (8.7, 18.2) 9.9 (6.6, 20.2) 2.0 (−8.6, 9.1) 0.088
.6 (6.6, 9.3) 7.7 (6.7, 9.2) −0.3 (−2.3, 1.6) 0.609
.7 (4.2, 11.3) 6.9 (4.5, 10.7) −0.8 (−4.3, 4.5) 0.636
.1 (0.1, 2.1) 1.3 (0.2, 2.5) −0.4 (−2.5, 1.6) 0.345
8.0 (23.6, 31.8) 26.9 (24.5, 33.9) 0.01 (−5.5, 4.9) 1.000
.8 (0.8, 5.9) 1.6 (0.8, 4.8) 0.7 (−2.3, 3.8) 0.334
.6 (1.6, 4.1) 2.4 (1.3, 4.9) 0.2 (−2.3, 2.3) 0.650
.3 (−1.4, 24.9) 3.3 (−1.4, 13.1) 2.8 (−11.9, 19.1) 0.329
8.0 (53.1, 115.4) 83.4 (62.3, 129.9) −7.4 (−45.7, 35.6) 0.727
8.3 (53.2, 64.8) 60.7 (51.9, 67.5) −1.1 (−8.7, 7.3) 0.547
9.8 (12.3, 24.2) 18.6 (10.1, 24.5) −0.7 (−8.2, 8.9) 0.907
n women.
ber (%) of divergent pairs. P-values calculated using McNemar’s test.
= 2.7, MOZ1= 31.7, MOZ2= 1.4, MOZ3= 2.9, MOZ4= 0.4, MOZ5= 52.6,







































































Figure 2 IgM antibody responses to merozoite antigens (A) and P. falciparum (Pf) lysate (B). Seroprevalence is represented by bars as
the % of responders; plasma levels are represented by dot plots, with horizontal lines indicating median values. Data from children with SM is
shown as shaded bars/dots; data from children with UM is shown as open bars/dots. Results of matched comparisons are reported in the x
axis as the number (%) of divergent pairs for IgM seroprevalence, and the median difference (inter-quartile range) of IgM levels between SM
and UM. P-values were calculated using McNemar’s or Sign test. All comparisons were corrected by the Monte Carlo permutation test (1000 random
permutations). Thresholds for seroprevalence (OD): MSP-119 = 0.605, EBA-175=0.514, AMA-1= 0.554, DBLα=0.444, P. falciparum lysate= 0.057. Median
difference (inter-quartile range) of IgG levels against uninfected erythrocytes lysate between SM and UM=−0.02 [−0.2, 0.1], P=1.000.
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dren with SM (P= 0.013), although no significant differ-
ences were found for IL-1β concentrations. Conversely,
children with SM had lower levels of TGF-β1 and IL-12
(P< 0.001 and P= 0.039, respectively; Figure 3B and 3C),
and lower prevalence of detectable IL-12 concentrations
than matched UM controls (P= 0.011; Figure 3C). IL-5
and TNF-β were excluded from the statistical analysis
since levels in most samples were below the limit of de-
tection (109/134 [81%] for IL-5 and 132/134 [99%] for
TNF-β). Overall, there were weak or moderate correla-
tions within cytokine responses (Additional file3), with
the exception of IL-6 and IL-10 (Spearman’s rho=
0.8682, P< 0.001). No significant correlations were
found between antibodies and cytokines.
Stratification by severe clinical presentations showed
that children with ARD had higher levels of IL-10
(P= 0.032) and IL-6 (P= 0.002) and lower levels of TGF-
β1 (P= 0.002) compared to their controls (Additional
file2). TGF-β1 concentrations were also reduced in the
prostration group (P=0.007).
IL-12 concentrations were associated with a reduction
of parasite densities when all children were included in
the analysis (0.69 [95% CI 0.54, 0.90], P=0.006) and in-
cluding only children with SM (0.62 [95% CI 0.44, 0.89],
P=0.010), but the association was not found in children
with UM (0.88 [95% CI 0.58, 1.33], P= 0.528). On the
other hand, higher concentrations of IL-10 were asso-
ciated with an increase in parasite densities in all groups
(all children: 2.44 [95% CI 1.58, 3.77], P< 0.001; SMcases: 2.59 [95% CI 1.37, 4.92], P = 0.004; UM controls:
2.62 [95% CI 1.38, 5.01], P = 0.004).
Discussion
Results of this case–control study show that SM in Mo-
zambican children under five years of age is associated
with low IgM responses to blood stage antigens and low
IgG responses to a rosetting DBLα domain [33], as well
as with high levels of pro-inflammatory IL-6 and low
levels of TGF-β1 and IL-12. In contrast to previous
reports, this study did not find differences in IgG
responses against MSP-119 [7], AMA-1 [40] or IEs sur-
face antigens [10], possibly due to different definitions of
SM clinical presentations and levels of endemicity in the
study settings.
Although the observational approach of the study does
not allow determining if lower levels of antibodies are
the cause or the consequence of a severe infection, the
fact that immunoglobulin reduction was not uniform
strongly argues against a general impairment of immune
response as a consequence of SM. The reduction of anti-
DBLα IgG suggests that DBLα domains involved in roset-
ting are an important target of immunity against SM,
both for presentations such as ARD, prostration and SA
(and being the lack of association with MS probably at-
tributable to low sample size). IgG antibodies to several
DBLα domains have already been linked to natural acqui-
sition of immunity [33,41] and to reduced risk of clinical
malaria [42]. The finding is further supported by a nega-
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Figure 3 Plasma concentrations of cytokines and chemokines. (A) Pro-inflammatory cytokines, (B) immuno-regulatory/anti-inflammatory
cytokines, (C) Th1 cytokines, (D) pro-inflammatory chemokine and (E) Th2 cytokine. Percentage of detectable cytokines/chemokines is
represented by bars; concentrations are represented by dot plots, with horizontal lines indicating median values. Data from children with SM is
shown as shaded bars/dots; data from children with UM is shown as open bars/dots. Results of matched comparisons are reported in the x axis
as the number (%) of divergent pairs for cytokine/chemokine prevalence, and the median difference (inter-quartile range) of cytokine/chemokine
concentrations between SM and UM (in ng/mL for TGF-β1). P-values were calculated using McNemar’s or Sign test. All comparisons were
corrected by the Monte Carlo permutation test (1000 random permutations).
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able to reduce parasite densities through disruption of
rosettes, a mechanism that has been associated with pro-
tection from SM [43]. Conversely, no difference was found
for IgG against surface antigens of R29 IEs, the parasite
from which DBLα was cloned [33], suggesting that other
R29 var1-PfEMP1 domains and other antigens on the sur-
face of IEs may be masking epitope-specific DBLα
responses. Despite the absence of differences between
clinical groups, prevalence of recognition of R29 surface
antigens was high. R29 predominantly expresses a group
A PfEMP1 [44], to which antibodies are rapidly acquired
during early childhood [41,45]. On the other hand, no sig-
nificant recognition of the pregnancy-specific CSA-bind-
ing parasites was detected, in contrast with a recent study
that suggests recognition of VAR2CSA DBL5E domain in
young children [45].
This study also reports a reduction of IgM responses to
blood stage antigens in children with SM compared to
UM, in agreement with findings from previous studies[12-14]. IgM levels have been associated with reduced risk
of malaria in children and adolescents [46,47] and
negatively correlated with parasite densities [46], sug-
gesting that IgM are capable of controlling Plasmodium
infection through early limitation of parasite growth
[48] or through blocking of pro-inflammatory TNF produc-
tion [49].
The differences in antibody levels between children
with SM and UM observed in this study were not attrib-
utable to a lower exposure to P. falciparum in SM cases,
since children with SM had similar levels of IgM and
even higher IgG against total P. falciparum antigens
compared to children with UM. Moreover, differences
could not be explained by a longer progression of the
disease in SM cases because the number of days with
symptoms of malaria prior to enrolment was similar to
that in the UM group. Importantly, a higher number of
previous SM episodes were reported among cases. This
observation may indicate that host genetic factors can
predispose children to develop SM [50] or that children
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ure to P. falciparum antigens, producing immunological
tolerance and increasing susceptibility to subsequent
malaria infections [51]. Also, an episode of SM may ren-
der children more susceptible to future severe episodes,
maybe through an expansion of exhausted T cells or
atypical B cells [52,53] which may impair the develop-
ment of an adequate protective immune response.
SM was also found to be associated with alterations of
the fine balance between pro-inflammatory and anti-
inflammatory cytokines [22]. Children with SM showed
higher levels of pro-inflammatory IL-6 [16,54], had more
detectable levels of IL-1β and insufficient immuno-
regulatory TGF-β1, which has been shown to counter-
balance the pro-inflammatory response [22]. Although
levels of immuno-regulatory IL-10 were significantly
increased in children with ARD [55] this response did
not seem to be sufficient to control the IL-6 imbalance.
As previously reported by Lyke et al. in Mali [54], TNF
did not differ between SM and UM in Mozambican chil-
dren, an observation that is in contrast to other studies
suggesting that TNF is the major cytokine involved in the
pro-inflammatory response in SM [56,57]. It is possible
that IL-6 and IL-10 levels reached by SM children at ad-
mission had already down regulated initial TNF pro-
inflammatory response [19,20]. Children with SM were
also characterized by lower levels of IL-12 [22,57], a cyto-
kine previously associated with anti-malarial immunity
[15,17,22]. Consistently, a negative association between
IL-12 concentrations and parasite densities was found.
Haemozoin phagocytosis by monocytes but also IL-10
may be acting as IL-12 inhibitors in SM [57,58]. Overall,
this study suggests that children with SM may have an
immature immune system typical of early childhood,
consisting in a greater dependence on innate immune
responses for protection against infections [59], lower
Th1-polarizing cytokine responses (i.e. IL-12) [60,61] and
a bias of Toll-Like receptor-mediated responses towards
acute phase (i.e. IL-1β and IL-6) and IL-10 responses
[60]. Therefore, an immune system still under develop-
ment, together with an insufficient or impaired antibody
response at this age, may limit the ability to contain in-
fection, lead to an exacerbated inflammatory response
and increase the risk of developing SM.
The present study is limited by a number of factors.
First, antibodies and cytokines measured in peripheral
blood at a single time point may not reflect the course
of infection or the response in specific organs where
parasite sequestration is occurring. Second, it was not
possible to control for the effects that co-infection with
HIV or helminthes may have on anti-malarial immunity
[62,63]. Nevertheless, clinical data suggests that AIDS
was infrequent in patients from the present study. Fi-
nally, the high degree of overlap in severe symptoms,which is otherwise common in endemic areas [64], to-
gether with the limited sample size of clinical groups,
may have hampered the identification of immunological
correlates that are particular to a clinical form of SM.
Conclusions
These data supports a role for specific IgM to P.
falciparum and IgG to rosetting PfEMP1 domains in
controlling SM. Also, imbalanced pro-inflammatory
cytokine responses may exacerbate the severity of infec-
tion in children. This information is of relevance to
understand how immunity to SM is acquired in early
childhood and also for the design of strategies to control
life-threatening malaria. In particular, subunit vaccines
containing DBLα epitopes from rosetting PfEMP1 might
potentially elicit functional antibodies that reduce the
risk of SM in children. Prospective cohort studies asses-
sing IgG isotypes and functionality of antibodies, to-
gether with detailed phenotype analysis of cytokine-
producing cells will help to understand the mechanisms
underlying natural acquisition of immunity to malaria se-
vere disease.
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